BPG is committed to discovery and dissemination of knowledge
Randomized Controlled Trial
Copyright: ©Author(s) 2026.
World J Gastroenterol. Nov 28, 2026; 32(44): 122850
Published online Nov 28, 2026. doi: 10.3748/wjg.122850
Table 3 Medication adherence and eradication outcomes, mean ± SD/n (%)
Outcome
Control (n = 66)
Trimebutine (n = 66)
P value
Mean adherence, %85.0 ± 33.081.6 ± 36.80.764
Adherence ≥ 80%53 (80.3)52 (78.8)> 0.999
Completed 14-day regimen59 (89.4)59 (89.4)> 0.999
Lost to follow-up for UBT9 (13.6)11 (16.7)0.809
ITT eradication n/N (%), (95%CI)50/66 (75.8) (64.2-84.5)49/66 (74.2) (62.6-83.3)> 0.999
PP eradication, n/N (%), (95%CI)50/57 (87.7) (76.8-93.9)49/55 (89.1) (78.2-94.9)> 0.999


Write to the Help Desk